Portola Pharmaceuticals   Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: South San Francisco CA United States (2003)
Status: Acquired by Alexion (2020) → now AstraZeneca (2020)

Organization Overview

First Clinical Trial
2006
NCT00375609
First Marketed Drug
2017
betrixaban (bevyxxa)
First NDA Approval
2017
betrixaban (bevyxxa)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Portola Pharmaceuticals | Portola Pharmaceuticals Inc. | PORTOLA PHARMS INC